# Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab

> **NCT04533737** · PHASE4 · TERMINATED · sponsor: **LEO Pharma** · enrollment: 113 (actual)

## Conditions studied

- Plaque Psoriasis
- Psoriasis Vulgaris
- Psoriasis

## Interventions

- **BIOLOGICAL:** Brodalumab
- **OTHER:** Placebo
- **BIOLOGICAL:** Guselkumab

## Key facts

- **NCT ID:** NCT04533737
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-12-17
- **Primary completion:** 2022-09-08
- **Final completion:** 2022-12-07
- **Target enrollment:** 113 (ACTUAL)
- **Why stopped:** The recruitment was terminated early due to delays and slow recruitment that significantly jeopardized the trial timelines. There were no safety concerns related to the early termination of the trial.
- **Last updated:** 2025-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04533737

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04533737, "Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04533737. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*